A drug underdevelopment may provide another pathway to lowering LDL levels.
Joseph E. Cruz, PharmD, BCPS
Advertisement
Articles by Joseph E. Cruz, PharmD, BCPS
Advertisement
Latest Updated Articles
- Targeting LDL via PCSK-9 from a Different Pathway
July 12th 2017
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
3
FDA Approves Brytly for OTC Eye Redness Relief
4
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
5